Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

Contributed by: PR Newswire

Tags

LUNDBECK-Amlenetug

More Like This

Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

Exidavnemab phase 2a study expanded to include MSA patients

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment